MCC Inhibitors

MCC inhibitors refer to compounds that target and inhibit the activity of the mitotic checkpoint complex (MCC), a crucial component involved in regulating the cell cycle during mitosis. The MCC functions as a safeguard to ensure accurate chromosome segregation by preventing the premature progression from metaphase to anaphase until all chromosomes are correctly aligned on the mitotic spindle. It achieves this by inhibiting the anaphase-promoting complex/cyclosome (APC/C), a key ubiquitin ligase responsible for marking specific proteins for degradation, thereby controlling the metaphase-anaphase transition. MCC is composed of several key proteins, including Mad2, BubR1 (or Bub1), Bub3, and Cdc20, which together form a regulatory network ensuring the proper timing of anaphase onset. When MCC is active, it binds to and inhibits APC/C, thus delaying cell cycle progression until chromosomal alignment is achieved.

The inhibition of MCC activity is of interest due to its potential to disrupt the precise timing mechanisms involved in cell cycle control, particularly in mitosis. By inhibiting MCC, the checkpoint that halts the transition to anaphase is disabled, allowing premature progression through mitosis even if the chromosomes are not properly aligned. This can lead to aneuploidy, where cells have abnormal numbers of chromosomes, a phenomenon closely linked to genomic instability. MCC inhibitors typically function by interfering with the formation of the MCC complex or by preventing its interaction with APC/C, which disturbs the regulatory control of mitosis. These inhibitors are also of interest to researchers studying cell cycle regulation and the mechanisms that ensure genetic fidelity during cell division, as perturbations in these processes can illuminate key aspects of mitotic control and checkpoint signaling pathways.